Profound Medical (PROF) unveiled new, real-world data from the Busch Center. The data, marking the center’s milestone of 500 completed TULSA Procedures, demonstrate the procedure’s versatility and success in treating a broad spectrum of prostate diseases, severities, and aggressions using an incision-free, MRI-guided approach.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROF:
- Profound Medical to Present at Stifel 2025 Healthcare Conference
- IBM partners with Anthropic, Dell boosts long-term view: Morning Buzz
- Profound Medical Reports Record Preliminary Q3 2025 Revenue
- Profound Medical sees Q3 revenue $5.2M-$5.3M vs. $2.8M last year
- Profound Medical Expands TULSA Program in Texas, Enhancing Prostate Treatment Access